Alzheimer’s Disease 2026: Where Are We?
Description
The landscape of Alzheimer’s disease diagnosis and treatment is evolving rapidly, driven by advances in biomarker science, earlier disease detection, and the emergence of disease-modifying therapies. These developments are transforming clinical practice and creating new opportunities to identify and intervene in the disease before the onset of significant cognitive impairment.
This presentation will provide an overview of the latest advances in Alzheimer’s disease diagnosis and treatment. Participants will review the expanding role of fluid and imaging biomarkers in detecting Alzheimer’s disease across the disease continuum, including the preclinical stage, and examine how these tools are improving diagnostic precision, patient selection, and disease monitoring. The session will also discuss the current landscape of disease-modifying therapies, their integration into clinical practice, and the implications of these advances for personalized patient care and future therapeutic development.
Attendees will leave with a greater understanding of the current state of Alzheimer’s disease diagnosis and management and practical insights into how biomarkers and disease-modifying therapies are reshaping the early identification, treatment, and long-term care of individuals at risk for or living with Alzheimer’s disease.